Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Lexicon Pharmaceuticals, Inc.'s obesity drug, LX9851, is the subject of an exclusive license agreement with Novo Nordisk worth up to $1bn.
I had the pleasure of catching up with Mike at JPM Week 2025, where he sized up the scope of the health burden that Lexicon are addressing.
Yours sincerely,
Dr. Adil Ali
FLIM LABS is redesigning the tools of fluorescence-lifetime imaging to enable broader access across medicine, pharma, and environmental science.
Allucent are helping small- to mid-sized biotechs stay nimble.
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
Peter DeYoung lends insights on the strategic approach behind Piramal Phama’s expansion and growth.
